Glaukos Co. (NYSE:GKOS – Get Free Report)’s share price gapped down before the market opened on Friday after the company announced weaker than expected quarterly earnings. The stock had previously ...

Glaukos' fourth-quarter results showcase a strong uptick in revenues. However, continued operating loss and rising OpEx ...

Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Truist Financial analyst Richard Newitter maintained a Buy rating on Glaukos (GKOS – Research Report) today. The company’s shares closed ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and ...

Principal Financial Group Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...

Glaukos’ revenues have surpassed estimates in the first nine months of 2024 due to high demand for its products. Consequently, the company raised its full-year 2024 revenue guidance to $377-$379 ...